Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
5/31/2026, 12:00:00 AM
On May 31, 2026, presented positive preliminary Phase 1/2 data for linvoseltamab at the ASCO annual meeting; estimated >5% price impact due to positive clinical results for a key pipeline drug, expected.
Korean Translation
2026년 5월 31일, ASCO 연례회의에서 린보셀타맙의 임상 1/2상 긍정적 데이터 발표함. 임상 결과에 따른 5% 이상의 주가 영향이 예상됨.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day in New York City to provide updates on strategy and long-term financial plans is scheduled. Impact estimated at >=1% as analyst days usually provide incremental updates; the event is scheduled.
9/16/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's Q2 FY2027 earnings release is scheduled.
8/20/2026, 12:00:00 AM
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Kratos Defense & Security Solutions Inc (KTOS) · Earnings Release
Kratos is expected to announce its Q2 2026 earnings on 2026-08-06, with analysts forecasting an EPS of approximately $0.14. This event is estimated to have a ≥5% price impact and is scheduled.
8/6/2026, 12:00:00 AM